The Chain: Protein Engineering Podcast

How is BindCraft, the automated pipeline for de novo protein binder design, changing the protein design industry? Martin Pacesa, assistant professor of pharmacology at the University of Zurich, joins The Chain to discuss how BindCraft is helping non-protein designers learn how to design proteins—and how the role of the protein designer will evolve. With host Chris Bahl, their conversation explores how BindCraft may help with drug development, its role in the democratization of tools and resources, and how to work more collaboratively with AI models. Pacesa will also be speaking at May’s PEGS Summit in Boston.  
Links from this episode:  
AI Proteins 
UZH - Institute of Pharmacology and Toxicology  
University of Zurich 
Models & Molecules Podcast

T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recognition of multiple targets, prospects for peptide MHC engagers and NK cells engagers, and the application of these modalities to oncology and beyond. 
Links from this episode:  
University of Toronto, Department of Immunology
University of Toronto
Cullinan Therapeutics
Masonic Cancer Center

During last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderated by Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, the discussion centered around whether half-life extended peptides will eventually replace multispecific antibodies.

Links from this episode:  
PEGS Europe 
PEGS
Synthetic Design Lab
Genentech
Eli Lilly and Company
Lust for Life Science B.V.

How has immunotherapy evolved in the last decade? In this episode of The Chain, Laszlo Radvanyi, professor of immunology at the University of Toronto, discusses his years-long research on cancer immunotherapy, including his time at MD Anderson, with host Rakesh Dixit. He shares his thoughts on agonist antibodies, the true breakthroughs that are moving the needle for patients, reducing the CD-28 pathway so that it doesn’t produce cytokine toxins, and what is the next frontier in immunotherapy. 

Links from this episode:  
EpiVax
University of Toronto, Department of Immunology 
University of Toronto

December 13, 2025 | What is next for immunogenicity? In this episode of The Chain, Vibha Jawa, chief scientific officer at EpiVax, provides her thoughts and insights on BiTE molecules, pegylated molecules, and other biologic molecules and their impact on cancer treatment and research with host Rakesh Dixit. Jawa shares the most rewarding project she’s worked on and what therapeutic modality she sees being picked up in the next decade, as well as advice for the next generation of scientists, such as why it’s important to be hands-on with research and be collaborative with others.  

Links from this episode:  
EpiVax